更新于：2024-05-01
Meglumine Antimoniate
锑酸葡甲胺
更新于：2024-05-01
概要
基本信息
结构
分子式C7H18NO8Sb |
InChIKeyJLGCKKAHTCRITP-SESJOKTNSA-O |
CAS号133-51-7 |
查看全部结构式(2)
关联
42
项与 锑酸葡甲胺 相关的临床试验Comparison of Efficacy of Intravenous Versus Intramuscular Injection Meglumine Antimoniate in patients of Cutaneous Leishmaniasis
Evaluating the effectiveness of intralesional injection of Glucantime® plus cotton boll extract compared to intralesional injection of Glucantime® plus cryotherapy in patients infected with Leishmania tropica
Tofacitinib Associated With Meglumine Antimoniate in the Control of American Tegumentary Leishmaniasis. A Randomized and Controlled Clinical Trial.
100 项与 锑酸葡甲胺 相关的临床结果
登录后查看更多信息
100 项与 锑酸葡甲胺 相关的转化医学
登录后查看更多信息
100 项与 锑酸葡甲胺 相关的专利（医药）
登录后查看更多信息
1,244
项与 锑酸葡甲胺 相关的文献（医药）2024-02-15Journal of vector borne diseases
Treatment of Cutaneous Leishmaniasis lesion caused by Leishmania major Using Leech Therapy in BALB/c Mice.
Article
作者: Leila Shirani-Bidabadi
BACKGROUND OBJECTIVES:
Amphotericin B, Allopurinol, Glucantime and Beta-Glucan are the main drugs currently used for the treatment of cutaneous leishmaniasis. In present study, we evaluated the effect of medical leeches on BALB/c mice models infected with Leishmania parasites.
METHODS:
To create animal models of leishmaniasis, BALB/c mice were inoculated with the standard Leishmania major strain MRHO / IR / 75 / ER. Treatment was performed through blood sampling with leeches. We used medical leech (Hirudo medicinalis) species. This leech is a European medicinal leech, one of several species known used as medicinal leech. 22 mice infected with Leishmania major were used for the tests .The studied mice were divided into two groups which were named with the letters L and D. The duration of blood sampling was 25 min for initial treatment, 20 min for the 2nd blood sampling and 15 min for the third times and onwards. Meglumine antimoniate (Glucantime) is a pentavalent antimony (SbV) that recommended by the World Health Organization as a golden standard treatment for all kind of leishmaniasis, but many side effects are still reported. Criteria for anti-leshmania assessment of Leech were including: Leech saliva has an anti-leishmania effect by acting on the purin pathway. Leech saliva prevents the growth and multiplication of Leishmania by a mechanism of action similar to Glucantim (breaking ATP).
RESULTS:
The duration of leech treatment in BALB/c mice infected with L.major parasites was about 6-8 weeks. Out of the 22 leishmaniasis mice models that underwent treatment, 13 survived until the end of the treatment duration. The recovery rate was about 56%; lesions improved in five out of the 13 surviving mice models. Paired t-test showed a significant difference between the mean wound size at the beginning of treatment and the 8th week of treatment (PV <0.0001).
INTERPRETATION CONCLUSION:
Considering the fact that the standard drugs for the treatment of leishmaniasis have many side effects, alternative therapies such as leech therapy can be effectively used to treat these chronic wounds. There are about 20 active substances in leech saliva. These substances include antistasin, eglins, guamerin, hirudin, saratin, bdellins, complement, and carboxypeptidase inhibitors. Leech saliva is an anticoagulant, anti-inflammation and prevents the platelet. Leech therapy was effective in treating leishmaniasis wounds in BALB/c mice. In this study, there was complete wound healing in 56% of the mice models.
2024-02-09International journal for parasitology. Drugs and drug resistance
Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis.
Article
作者: Juliana Figueiredo Peixoto ; Luiz Filipe Gonçalves-Oliveira ; Franklin Souza-Silva ; Luzia Monteiro de Castro Côrtes ; Léa Cysne Finkelstein ; Geovane Dias-Lopes ; Beatriz Ferreira de Carvalho Patricio ; Carolina Guimarães de Souza Lima ; Helvécio Vinícius Antunes Rocha ; Fernando de Carvalho da Silva ; Vitor Francisco Ferreira ; Bernardo Acácio Santini Pereira ; Carlos Roberto Alves
Leishmaniasis is a disease caused by Leishmania spp., affecting millions of people around the world. For decades, its treatment has been based on pentavalent antimonials, which notoriously cause toxic side effects in patients. In this study, epoxy-α-lapachone incorporated into an oil-in-water-type microemulsion (ELAP-ME) and meglumine antimoniate (MA) were assayed in monotherapy and in combination (ELAP-ME/MA) in BALB/c mice infected with Leishmania (Leishmania) amazonensis. In general, there was a reduction in paw lesion size (up to 37% reduction) and decreases of parasite loads in the footpad (∼40%) and lymph nodes (∼31%) of animals treated with ELAP-ME/MA, when compared to the non-treated control groups. Analyses of serum biochemical parameters revealed that the ELAP-ME/MA showed lower renal and hepatic toxicity when compared to MA 2-doses/week monotherapy. These findings indicate that the ELAP-ME/MA combination may be a promising approach for the treatment of cutaneous leishmaniasis.
2024-02-01Iranian journal of medical sciences
Adipose-Derived Stem Cells' Secretome Attenuates Lesion Size and Parasite Loading in Leishmaniasis Caused by Leishmania Major in Mice.
Article
作者: Iman Khodkar ; Jasem Saki ; Reza Arjmand ; Ghasem Saki ; Layasadat Khorsandi
Background:
Stem cell-derived secretome (SE) released into the extracellular space contributes to tissue repair. The present study aimed to investigate the impact of isolated secretome (SE) from adipose-derived mesenchymal stem cells (ASCs) on Leishmania major (L. major) lesions in BALB/c mice.
Methods:
This experimental study was conducted at Ahvaz University of Medical Sciences (Ahvaz, Iran) in 2021. Forty female BALB/c mice were infected with stationary phase promastigotes through intradermal injection in the bottom of their tail and randomly divided into four groups (n=10 per group). The mice were given SE (20 mg/mL), either alone or in combination with Glucantime (GC, 20 mg/mL/Kg), meglumine antimoniate (20 mg/mL/Kg) for the GC group, and phosphate-buffered saline (PBS) for the control group. After eight weeks, the lesion size, histopathology, the levels of Interleukin 10 (IL-10), and Interleukin 12 (IL-12) were assessed. For the comparison of values between groups, the parametric one-way ANOVA was used to assess statistical significance.
Results:
At the end of the experiment, the mice that received SE had smaller lesions (4.56±0.83 mm versus 3.62±0.59 mm, P=0.092), lower levels of IL-10 (66.5±9.7 pg/mL versus 285.4±25.2 pg/mL, P<0.001), and higher levels of IL-12 (152.2±14.2 pg/mL versus 24.2±4.4 pg/mL, P<0.001) than the control. Histopathology findings revealed that mice treated with SE had a lower parasite burden in lesions and spleen than the control group.
Conclusion:
The current study demonstrated that ADSC-derived SE could protect mice infected with L. major against leishmaniasis.
100 项与 锑酸葡甲胺 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 利什曼病 | 批准上市 | - |  Sanofi更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 32 | 餘鬱選鹽鏇夢簾積願鹹(遞餘壓醖鏇繭膚淵遞衊) = 醖繭壓憲鑰齋餘蓋鬱憲 夢夢遞構築淵憲醖醖醖 (淵構蓋觸醖淵蓋齋糧壓 ) | 积极 | 2023-07-03 | |||
Sbv + Placebo | 餘鬱選鹽鏇夢簾積願鹹(遞餘壓醖鏇繭膚淵遞衊) = 鑰襯構鑰蓋選蓋廠鏇觸 夢夢遞構築淵憲醖醖醖 (淵構蓋觸醖淵蓋齋糧壓 ) | ||||||
临床3期 | 180 | 簾簾鑰選膚獵衊簾築膚(糧窪艱齋遞醖鏇願顧襯) = 積遞顧蓋構醖顧顧鏇獵 簾醖構襯壓製窪夢鹽憲 (糧衊鏇壓顧簾憲糧襯憲 ) | - | 2022-07-08 | |||
簾簾鑰選膚獵衊簾築膚(糧窪艱齋遞醖鏇願顧襯) = 鹽醖網夢鬱窪廠簾醖鹹 簾醖構襯壓製窪夢鹽憲 (糧衊鏇壓顧簾憲糧襯憲 ) | |||||||
临床3期 | 粘膜皮肤利什曼病 一线 | - | Thermotherapy | (顧鏇積壓鹹蓋餘遞齋鹹) = The side effects of meglumine antimoniate included myalgia, arthralgia, headache and fever. Regarding thermotherapy, the only side effect was pain at the lesion area four days after the initiation of treatment. 範窪繭築選鹹簾遞夢築 (艱醖製觸顧廠齋壓遞鹹 ) | 积极 | 2012-12-01 | |
临床3期 | 116 | (衊餘範壓憲積壓衊窪遞) = 夢襯壓蓋糧範觸鏇衊齋 鹽衊簾製製廠艱蓋範廠 (遞選鹽網餘網鬱齋鹽鑰, 5.7% ~ 28.7%) | 积极 | 2012-02-15 | |||
(衊餘範壓憲積壓衊窪遞) = 顧選鑰築艱鏇窪築觸壓 鹽衊簾製製廠艱蓋範廠 (遞選鹽網餘網鬱齋鹽鑰, 16.9% ~ 45.2%) | |||||||
N/A | - | 製糧廠壓蓋鑰鹹簾構夢(範膚製鹽淵鏇憲觸廠觸) = 網壓襯積襯廠顧築製網 蓋觸構襯鹽範繭築膚糧 (網製膚觸選襯築選醖憲, 3.59 ~ 14.26) | - | 2017-04-01 | |||
製糧廠壓蓋鑰鹹簾構夢(範膚製鹽淵鏇憲觸廠觸) = 壓齋鹹網餘築糧衊衊衊 蓋觸構襯鹽範繭築膚糧 (網製膚觸選襯築選醖憲, 14.48 ~ 29.58) | |||||||
N/A | 1,200 | 積範鬱鬱艱糧餘膚廠蓋(獵鬱範齋獵壓鑰糧網觸) = 網憲襯選獵選獵艱衊簾 遞夢衊鑰顧淵顧鏇膚築 (顧鹽觸顧顧襯壓蓋範壓 ) 更多 | - | 2022-05-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用